Wilson Bradley S

Gordon Mae O, Higginbotham Eve J, Heuer Dale K, Parrish Richard K, Robin Alan L, Morris Patricia A et al.

The OHTS-1 Endpoint Committee improved glaucoma incidence estimates and treatment effect calculations by 23%, highlighting its value in trials with co-morbidities.

Bhorade Anjali M, Wilson Bradley S, Gordon Mae O, Palmberg Paul, Weinreb Robert N, Miller Eydie et al.

This study found that monocular trials are no better than independent eye testing for assessing glaucoma medication response, as neither adequately determines treatment efficacy due to high inter-eye IOP correlation.

Barnett Edward M, Fantin Aldo, Wilson Bradley S, Kass Michael A, Gordon Mae O

This study found a low 10-year incidence of retinal vein occlusion (RVO) in ocular hypertension patients, with no significant difference between treated and untreated groups. Older age and larger cup-to-disc ratio were associated with RVO.